These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 35581611

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
    Studentova H, Rusarova N, Ondruskova A, Zemankova A, Student V, Skanderova D, Melichar B.
    Curr Oncol; 2022 Aug 03; 29(8):5475-5488. PubMed ID: 36005171
    [Abstract] [Full Text] [Related]

  • 3. Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy.
    Anraku T, Hashidate H, Nakahara A, Imai T, Kawakami Y.
    BMC Urol; 2023 Mar 18; 23(1):38. PubMed ID: 36934227
    [Abstract] [Full Text] [Related]

  • 4. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
    George G, Schmidt L, Tolat P, Riese M, Kilari D.
    J Immunother Cancer; 2020 Feb 18; 8(1):. PubMed ID: 32114501
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
    Brown LC, Zhu J, Desai K, Kinsey E, Kao C, Lee YH, Pabla S, Labriola MK, Tran J, Dragnev KH, Tafe LJ, Dayyani F, Gupta RT, McCall S, George DJ, Glenn ST, Nesline MK, George S, Zibelman M, Morrison C, Ornstein MC, Zhang T.
    J Immunother Cancer; 2022 Oct 18; 10(10):. PubMed ID: 36252996
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
    Miyauchi Y, Naito H, Tsunemori H, Tani R, Hasui Y, Miyake Y, Minamino T, Ishikawa R, Kushida Y, Haba R, Sugimoto M.
    J Med Case Rep; 2021 Oct 15; 15(1):508. PubMed ID: 34649593
    [Abstract] [Full Text] [Related]

  • 11. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
    Gul A, Stewart TF, Mantia CM, Shah NJ, Gatof ES, Long Y, Allman KD, Ornstein MC, Hammers HJ, McDermott DF, Atkins MB, Hurwitz M, Rini BI.
    J Clin Oncol; 2020 Sep 20; 38(27):3088-3094. PubMed ID: 32491962
    [Abstract] [Full Text] [Related]

  • 12. Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report.
    Dionese M, Pierantoni F, Maruzzo M, Bimbatti D, Deppieri FM, Maran M, Gardiman MP, Basso U.
    Anticancer Drugs; 2021 Feb 01; 32(2):222-225. PubMed ID: 32868643
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.
    Studentova H, Zemankova A, Spisarova M, Skanderova D, Tudos Z, Melichar B, Student V.
    Medicina (Kaunas); 2022 Feb 23; 58(3):. PubMed ID: 35334512
    [Abstract] [Full Text] [Related]

  • 15. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
    Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B.
    J Immunother Cancer; 2022 Nov 23; 10(11):. PubMed ID: 36328377
    [Abstract] [Full Text] [Related]

  • 16. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
    Mari R, Guerin M, Vicier C, Walz J, Bonnet N, Pignot G, Gravis G.
    Front Immunol; 2022 Nov 23; 13():984132. PubMed ID: 36189265
    [Abstract] [Full Text] [Related]

  • 17. Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.
    Grimm MO, Schmitz-Dräger BJ, Zimmermann U, Grün CB, Baretton GB, Schmitz M, Foller S, Leucht K, Schostak M, Zengerling F, Schumacher U, Loidl W, Meran J.
    J Clin Oncol; 2022 Jul 01; 40(19):2128-2137. PubMed ID: 35275706
    [Abstract] [Full Text] [Related]

  • 18. Case report: Complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors.
    Asano Y, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, Igarashi K, Higuchi T, Taniguchi Y, Morinaga S, Horimoto T, Nakai M, Kadono Y, Nojima T, Tsuchiya H.
    Front Immunol; 2022 Jul 01; 13():980456. PubMed ID: 36238308
    [Abstract] [Full Text] [Related]

  • 19. Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy.
    Sejima T, Masago T, Yoshida M, Nishi T, Kawabata Y, Tajima Y, Yumioka T, Honda M, Takenaka A.
    Int Cancer Conf J; 2021 Oct 01; 10(4):285-289. PubMed ID: 34567939
    [Abstract] [Full Text] [Related]

  • 20. Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney.
    Watanabe K, Sugiyama T, Otsuka A, Miyake H.
    Int Cancer Conf J; 2020 Jan 01; 9(1):32-35. PubMed ID: 31950015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.